{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:35:40Z","timestamp":1766068540941,"version":"3.48.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) poses a growing challenge to global public health, with regional disparities in disease burden becoming increasingly prominent. As the most populous continent, Asia is undergoing rapid demographic and socioeconomic transitions, and plays a critical role in shaping the evolutionary trajectory of the global MM burden. This study aims to assess the disease burden of multiple myeloma in Asian countries from 1990 to 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The data of this study were derived from the Global Burden of Disease Study 2021 database. We conducted a systematic analysis of the disease burden of MM in Asia from 1990 to 2021, covering four core dimensions: incidence, prevalence, mortality, and disability-adjusted life years (DALYs). To fully present the complexity of the disease burden, we also performed multiple analytical approaches, including trend analysis, gender-stratified analysis, regional comparative analysis, and ARIMA model prediction analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2021, incident cases of MM in Asia accounted for 35.8% of the global total, prevalent cases for 34.2%, deaths for 36.3%, and DALYs for 39.7%, making Asia a key contributing region to the global MM disease burden. From 1990 to 2021, the growth rates of the above indicators in Asia were significantly higher than the global average. Moreover, ARIMA model projections indicated that Asia\u2019s MM burden would follow a \u201cfirst increase, then stabilize\u201d trajectory by 2050, with a more prominent growth magnitude and higher prediction uncertainty observed in men. This disparity may reflect a combination of metabolic, lifestyle, and genetic factors East Asia and South Asia emerged as the core regions bearing the MM burden, while Central Asia exhibited the fastest growth rate in burden. High-income regions had higher MM diagnosis rates (reducing underreporting), whereas low-income regions faced significant underestimation of the actual burden due to limited diagnostic capacity. Additionally, as socioeconomic status decreased, the average age at death of MM patients advanced.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study confirms that Asia has become the primary driving region for the growth of the global MM burden, and its burden pattern is influenced by significant gender disparities, regional disparities, and socioeconomic disparities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1696768","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:30:02Z","timestamp":1766068202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden of multiple myeloma in Asian countries from 1990 to 2021 and trend prediction for 2050: an analysis based on the Global Burden of Disease Study 2021"],"prefix":"10.3389","volume":"12","author":[{"given":"Chengjun","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy.","volume":"5","author":"Lu","year":"2024","journal-title":"Mol Biomed"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival.","author":"Turesson","year":"2018","journal-title":"Eur J Haematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.ejca.2005.11.033","article-title":"Familial risks and temporal incidence trends of multiple myeloma.","volume":"42","author":"Altieri","year":"2006","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2017.1.498","article-title":"Management of multiple myeloma in the newly diagnosed patient.","volume":"2017","author":"Mateos","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/clinchem\/hvad148","article-title":"Screening in multiple myeloma and its precursors: Are we there yet?","volume":"70","author":"R\u00f6gnvaldsson","year":"2024","journal-title":"Clin Chem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: imwg consensus perspectives risk factors for progression and guidelines for monitoring and management.","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1118691","DOI":"10.3389\/fendo.2023.1118691","article-title":"Obesity and myeloma: clinical and mechanistic contributions to disease progression.","volume":"14","author":"Marques-Mourlet","year":"2023","journal-title":"Front Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019.","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1527198","DOI":"10.3389\/fpubh.2025.1527198","article-title":"Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.","volume":"13","author":"Zhuge","year":"2025","journal-title":"Front Public Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"04033","DOI":"10.7189\/jogh.14.04033","article-title":"Global, regional, and national burden and quality of care of multiple myeloma, 1990-2019.","volume":"14","author":"Geng","year":"2024","journal-title":"J Glob Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"104040","DOI":"10.1016\/j.critrevonc.2023.104040","article-title":"Revisiting the role of alkylating agents in multiple myeloma: up-to-date evidence and future perspectives.","volume":"187","author":"Costa","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1200\/JCO.22.02665","article-title":"Daratumumab, bortezomib, and dexamethasone for previously treated multiple myeloma.","volume":"41","author":"Huang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial.","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple Myeloma.","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40164-021-00213-6","article-title":"Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma.","volume":"10","author":"Okabe","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma.","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1007\/s00277-020-04378-8","article-title":"Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies.","volume":"100","author":"Gordillo","year":"2021","journal-title":"Ann Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00520-014-2552-1","article-title":"Treatment-related symptom management in patients with multiple myeloma: a review.","volume":"23","author":"Colson","year":"2015","journal-title":"Support Care Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.soncn.2017.05.008","article-title":"Evidence-based guidelines for preventing and managing side effects of multiple myeloma.","volume":"33","author":"Bertolotti","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ajpath.2015.11.003","article-title":"Inhibition of transforming growth factor-\u03b2 activation diminishes tumor progression and osteolytic bone disease in mouse models of multiple myeloma.","volume":"186","author":"Lu","year":"2016","journal-title":"Am J Pathol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3109\/10428194.2015.1011156","article-title":"Socioeconomic status is independently associated with overall survival in patients with multiple myeloma.","volume":"56","author":"Fiala","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B24","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1186\/s12885-021-08527-8","article-title":"The work of managing multiple myeloma and its implications for treatment-related decision making: a qualitative study of patient and caregiver experiences.","volume":"21","author":"Pritlove","year":"2021","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.1182\/blood-2022-163281","article-title":"A pilot plant based dietary intervention in MGUS and SMM patients with elevated BMI is feasible and associated with improvements in metabolic and microbiome biomarkers of progression.","volume":"140","author":"Shah","year":"2022","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy.","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"396","year":"2020","journal-title":"Lancet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-217050","article-title":"Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017.","volume":"79","author":"Jin","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.compeleceng.2019.04.013","article-title":"A smart system for short-term price prediction using time series models.","volume":"76","author":"Nguyen","year":"2019","journal-title":"Comput. Electrical Eng."},{"key":"B30","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/ckj\/sfac218","article-title":"Temporal trends in prevalence and mortality for chronic kidney disease in China from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019.","volume":"16","author":"Li","year":"2023","journal-title":"Clin Kidney J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","year":"2013","journal-title":"JAMA."},{"key":"B32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","article-title":"Incidence and mortality of multiple myeloma in China, 2006\u20132016: an analysis of the Global Burden of Disease Study 2016.","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review.","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, staging, and management of multiple myeloma.","volume":"9","author":"Padala","year":"2021","journal-title":"Med. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e420","DOI":"10.1016\/j.clml.2023.08.008","article-title":"Disparities in multiple myeloma treatment patterns in the united states: a systematic review.","volume":"23","author":"Gasoyan","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B37","doi-asserted-by":"publisher","first-page":"102848","DOI":"10.1016\/j.eclinm.2024.102848","article-title":"Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021.","volume":"76","author":"Zhou","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1111\/dom.15748","article-title":"The global burden of disease attributable to high body mass index in 204 countries and territories: findings from 1990 to 2019 and predictions to 2035.","volume":"26","author":"Chen","year":"2024","journal-title":"Diabetes Obesity Metabol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"20406207221086755","DOI":"10.1177\/20406207221086755","article-title":"Cardiovascular-specific mortality among multiple myeloma patients: a population-based study.","volume":"13","author":"Yin","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines\u00a7insights: multiple myeloma, version 3.2022.","volume":"20","author":"Callander","year":"2022","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1696768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:30:03Z","timestamp":1766068203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1696768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":40,"alternative-id":["10.3389\/fmed.2025.1696768"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1696768","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"1696768"}}